Crestline Management’s Estrella Immunopharma ESLA Stock Holding History

Crestline Management’s Portfolio ESLA Stock Details ESLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-21,990	Closed	-$233K	–	168
2023 Q1	$233K	Buy	+21,990	New	+$230K	0.03%	150

Other funds holding ESLA

Hunting Hill Global Capital New York $129M AUM 17.34% 1-Year Est. Return

Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Sea Otter Advisors Miami, Florida $1.78M AUM 2.28% 1-Year Est. Return

Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return

Robinson Capital Management Grosse Pointe Farms, Michigan $239M AUM 0.62% 1-Year Est. Return

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Crestline Management's ESLA Position: Q2 2023 in Review

Crestline Management sold out of Estrella Immunopharma (ESLA) in Q2 2023, closing a stake of 21,990 shares — an estimated $233K sold.

Crestline Management first reported a position in ESLA in Q1 2023 and held it in 1 quarter. The position peaked at $233K in Q1 2023. 9 funds tracked by Wall St. Rank hold ESLA as of Q2 2023.

Crestline Management reported no remaining Estrella Immunopharma position as of Q2 2023 after selling out during the quarter.
Crestline Management sold 21,990 Estrella Immunopharma shares in Q2 2023, an estimated $233K.
Crestline Management first reported a position in Estrella Immunopharma in Q1 2023 and held it in 1 quarter.
Crestline Management's Estrella Immunopharma position peaked at $233K in Q1 2023.
9 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2023.

Based on Crestline Management's 13F filing for Q2 2023, filed 14 Aug 2023.